학술논문
Phosphatidylserine enriched with polyunsaturated n‐3 fatty acid supplementation for attention‐deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo‐controlled trial
Document Type
article
Author
Sylvain Rheims; Vania Herbillon; Ségolène Gaillard; Catherine Mercier; Nathalie Villeuve; Frédéric Villéga; Claude Cances; Pierre Castelnau; Silvia Napuri; Anne de Saint‐Martin; Stéphane Auvin; Sylvie Nguyen The Tich; Patrick Berquin; Julitta deBellecize; Mathieu Milh; Pascal Roy; Alexis Arzimanoglou; Jacques Bodennec; Laurent Bezin; Behrouz Kassai; the investigators of the AGPI study group
Source
Epilepsia Open, Vol 9, Iss 2, Pp 582-591 (2024)
Subject
Language
English
ISSN
2470-9239
Abstract
Abstract Background Attention‐deficit hyperactivity disorder (ADHD) is a frequent comorbidity in children with epilepsy, which management mostly relies on the usual treatments of ADHD, especially methylphenidate. Supplementation with polyunsaturated n‐3 Fatty Acid (PUFA) has been proposed as an alternative therapeutic approach in ADHD without epilepsy but has never been evaluated in epilepsy‐associated ADHD. Methods A multicenter double blind randomized placebo‐controlled trial evaluating supplementation with PUFA, in eicosapentaenoic‐ and docosahexaenoic‐acid form, conjugated to a phospholipid vector (PS‐Omega3) in children aged >6 and